ABSTRAK
INTRODUCTION
Preeclampsia is one of the specific forms of hypertension in pregnancy that involves multiple organs. Preeclampsia generally occurs at the gestational age of 20 weeks and more. This disorder has a significant contribution to global maternal and perinatal morbidity as well as mortality. The incidence of preeclampsia ranges from 2-8% of all pregnancies. Furthermore, 10-15% of maternal deaths are associated with preeclampsia and eclampsia (Duley 2009 ).
The etiology and pathogenesis of preeclampsia have not yet been clearly defined. Many theories have evolved related to the etiology and pathogenesis of preeclampsia so that preeclampsia is also called 'the disease of theories' (Schlembach 2003) . Spiral artery remodeling abnormalities are considered as the main cause of preeclampsia. This results in placental hypoxia, increased oxidative stress and maternal systemic inflammatory responses (Naljayan & Karumanchi 2013) .
Until now the molecular pathogenesis of preeclampsia is largely unknown, but recent evidence shows that there has been a change in the expression of placental anti-angiogenic factors responsible for the clinical manifestations of preeclampsia. The level of Soluble Fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin produced by the placenta increase in the maternal circulation a few weeks before the onset of preeclampsia. This protein binds to the receptor-binding domains of vascular endothelial growth factor (VEGF) and placental growth factor (PlGF). Increased sFlt-1 level in the maternal circulation will decrease the amount of free VEGF and PlGF level resulting in endothelial dysfunction with clinical manifestations of hypertension, proteinuria, and other systemic symptoms of preeclampsia (Steinberg et al 2011 , Sibai 2016 In preeclampsia, there is a decrease in NO level. As a consequence, there is vasospasm of blood vessels which will lead to placental hypoxia and inflammatory reactions resulting in increased oxidative stress. Oxidative stress causes an imbalance between antioxidant agents and reactive oxygen species formation of free radicals which ultimately will cause systemic endothelial dysfunction. This systemic endothelial dysfunction causes clinical manifestations such as hypertension, proteinuria and thrombocytopenia (Nakagawa 2007) .
The relationship between VEGF and NO can be explained by the coupling of VEGF-NO pathway. Increased VEGF can enhance the production of endothelial Nitric Oxide Synthase (eNOS) and NO release from endothelial cells. The relationship between VEGF and NO that have been recognized, can be a new target in the prevention and treatment of preeclampsia. Currently, there is recombinant VEGF 121, called as exogenous VEGF (Shah 2007) . Treatment by administration of recombinant VEGF 121 is expected to increase the level of NO which can decrease maternal blood pressure, improve endothelial function and reduce the hypoxic placenta in preeclampsia. Research using human samples could not be done due to ethical problems so that researchers used animal studies, mice (Mus musculus) as a sample. Mice were selected in this study because they have a good adaptability in the laboratory environment and are genetically similar to human (Comiskey et al 2013 , Hladunewich & Karumanchi 2007 .
MATERIALS AND METHODS
This was an experimental analytical study with Randomized Control Trial (RCT) design. This study was performed in mice (Mus musculus) model who were adult females, with gestational age of fifteen days, to determine the difference in the level of nitric oxide (NO) among the serum of pregnant normal mice, pregnant mice model of preeclampsia without treatment of recombinant VEGF 121 and pregnant mice model of preeclampsia with recombinant VEGF 121 therapy.
The sampling process was performed on blood serum since various clinical manifestations of preeclampsia were often associated with decreased Nitric Oxide level in the maternal circulation. After obtaining the ethical approval from the research ethics committee of the Faculty of Veterinary Medicine, Universitas Airlangga, Surabaya, Indonesia, Number 648-KE, the research was begun with the process of fertilizing mice, by way of synchronization.
The following technic was used to fertilize the mice. Female mice aged 3 months, weighing 20-25 grams were injected with 5 IU Pregnant More Serum Gonadotropin (PMSG) hormone. 48 hours later were injected with 5 IU Human Chorionic Gonadotropin (hCG) hormone. The female mice were fertilized by mono mating system. Each one of female mice were inserted into a cage containing a male mice aged 7 months weighing ± 60 grams. 17 hours after mating process, the diagnosis of pregnancy was made by the appearance of copulatory plug (a plug covering the mice vagina from the cervix to the vulva).
On the 1st day of pregnancy, samples were divided into three groups as follows: K1: consisting of 9 normal pregnant mice, K2: consisting of 9 pregnant mice model of preeclampsia without treatment, and K3: consisting of 9 pregnant mice model of preeclampsia with recombinant VEGF 121 administration. During the 1st till the 4th day of pregnancy, the K2 and K3 group, were given anti-Qa-2 treatment of 10 ngiv to induce preeclampsia. (Sulistyowati et al 2017) . During the 11th until 14th day of gestational age, the K3 group was given a recombinant VEGF 121 injection of 125 mg/kilograms body weight once daily. On the 15th day, termination was performed in all three groups, then blood samples were collected from intra-cardiac in all groups of mice. From the existing samples, Elisa method was performed to determine the level of Nitrite Oxide in maternal plasma.
Data were analyzed using SPSS software (Software Package for Social Science). Kolmogorov-Smirnov statistical test was performed to see the significance of the data. If the data were significantly different, ANOVA statistical test was performed to compare the significance differences among the groups. The statistical calculation in this study used the significance level of 0.05 (confident interval of 95%) so that the p value of <0.05 can be interpreted as significant.
RESULTS
Recombinant VEGF 121 played a role in increasing the level of nitric oxide in mice (Mus musculus) model of preeclampsia significantly. Because of that, it is expected to be an option in prevention and therapy for preeclampsia.
The results of data analysis were obtained from 27 research samples meeting the inclusion and exclusion criteria divided into 3 groups. The first group (K1) were 9 normal pregnant mice. The second group (K2) were 9 pregnant mice of preeclampsia model without treatment. The third group (K3) were 9 pregnant mice of preeclampsia model receiving recombinant VEGF 121 therapy. Table 1 showed that NO level in the first group (K1) was 1.746±0.347, with minimum value of 1.00 µM, and maximum value of 2.28 µM, CI (1.479-2.013). NO level in second group (K2) was 1.167±0.380, with minimum value of 0.64 µM, and maximum value of 1.94 µM, . NO level in the third group (K3) was 2.164±0.556, with minimum value of 1.56 µM, and maximum value of 5.96 µM, CI (1.842-2.486).
To find out the difference of nitric oxide serum level among those three groups, Post Hoc Test was performed by means of LSD. The full test results was presented in Table 2 . 
DISCUSSION
Nitric Oxide is a compound that maintains normal dilated blood vessel conditions for fetoplacental perfusion and maintains vascular tone. Pregnancy with risk factors such as maternal disease and oxidative stress is a disturbance of these angiogenic factors (Steinberg et al 2011) . Decreased levels of Nitric Oxide (NO) in the maternal circulation have an important role in the occurrence of hypertension in pregnancy and can develop into preeclampsia. In several different studies the prognosis was poor in preeclampsia patients with low NO levels in maternal circulation (Markham & Funai 2014) .
Some previous studies found that the level of NO was lower in patients with severe preeclampsia: 3.04 ± 0.43 ng/mL, compared to normal pregnancy: 8.10 ± 1.62 ng/mL (p value=0.00 (>0.05) (Damayanti et al 2015) . In another study, the level of VEGF, PlGF and NO were lower in patient with severe preeclampsia, with p value of <0.005 (Saha et al 2013) . Research on human showed the lower level of VEGF in patient with preeclampsia at 8th-12th weeks of gestation (14.24 ± 8.73 ng/ml) than in normal pregnancy (96.88 ± 144.29 ng/ml) with p value = 0.044 <0.05 (Wiyono et al 2015) . Another study showed VEGF level in patient with preeclampsia (9.53 ± 1.02 ng / ml) and in normal pregnancy 17.41 ± 8.05 ng/ml with p value=0.00<0.05 (Roswendi et al 2014) . Low VEGF level was also associated with IUGR incidence. The average of VEGF level at IUGR was 9.4 ± 0.40 ng/ml and in normal pregnancy was 11.04 ± 1.77 ng/ml with p value=0.00<0.05 (Nirwanasari et al 2014) . Other results of the NO concentration were lower in preeclampsia but not statistically significant (Erdemoglu et al 2009) . Several previous studies of recombinant VEGF 121 were proven to improve the placental histopathological feature, fetal weight growth disorder of mice, and elevated serum levels of PlGF in preeclampsia model of mice (Anggraini 2015 , Prabowo 2015 . (Irawan et al 2016) .
Another study showed that recombinant VEGF 121 was proven to improve placental endothelial dysfunction of preeclampsia model mice, as evidenced by a lower average decrease in VCAM-1 expression (2.14) compared to the average value of mice without recombinant VEGF 121 therapy (2.94) (p value=0.035 <0.05) (Sondakh et al 2016) .
